Top Industry Leaders in the Pancreatic cancer Market
Latest Pancreatic Cancer Companies Updates:
Pfizer's acquisition of Biohaven Pharmaceutical Holding Company: Gains access to innovative pancreatic cancer drug candidate.
Bristol Myers Squibb's collaboration with IFM Therapeutics: Jointly developing a novel targeted therapy for pancreatic cancer.
Merck & Co.'s partnership with Velontra Biosciences: Teams up to explore potential synergies in their respective pancreatic cancer pipelines.
Eli Lilly's Zydiso (nalurimide): Approved by the FDA for second-line treatment of pancreatic cancer, expanding treatment options.
Roche's Tecentriq (atezolizumab): Received breakthrough therapy designation from the FDA for combination use in early-stage pancreatic cancer.
AstraZeneca's Imfinzi (durvalumab): Market authorization extended in Europe for maintenance treatment of resectable pancreatic cancer.
List of Pancreatic cancer Key companies in the market:
- Pharmacyte Biotech Inc. (U.S.)
- ncoGenex Pharmaceuticals Inc. (U.S.)
- Oncolytics Biotech (Canada)
- Diffusion Pharmaceuticals (U.S.)
- Polaris Pharmaceuticals, Inc. (U.S.)
- Sun BioPharma, Inc. (U.S.)
- Midatech Pharma PLC (U.K.)
- Eli Lilly and Company (U.S.)
- Celgene Corporation (U.S.)
- F. Hoffmann-La Roche AG (Switzerland)
- Amgen, Inc. (U.S.)
- Novartis International AG (U.S.)
- Clovis Oncology (U.S.
